Malaysia vs Switzerland: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Malaysia
93.0%
in 2025
Switzerland
92.0%
in 2025
Malaysia rank
51st
Switzerland rank
54th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Malaysia
- Switzerland
How they compare
Malaysia currently reports 93.0% against 92.0% in Switzerland, a difference of 1.0%.
The two have swapped places 3 times across 18 shared years of data; in 2008 it was Switzerland ahead.
Malaysia ranks 51st and Switzerland ranks 54th of 192 countries.
Switzerland has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Malaysia | Switzerland | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 19.0% | 19.0% | Switzerland |
| 2010s | 0.0% | 71.6% | 71.6% | Switzerland |
| 2020s | 73.3% | 89.2% | 15.8% | Switzerland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Malaysia or Switzerland?
- Malaysia, at 93.0% against 92.0% in Switzerland as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Malaysia and Switzerland?
- 1.0%, with Malaysia ahead.
- How many years of comparable data are there for Malaysia and Switzerland?
- 18 years are reported by both, from 2008 to 2025.
- How do Malaysia and Switzerland rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Malaysia ranks 51st and Switzerland ranks 54th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.